Company news

Equillium, Inc. news in 2024

Equillium, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Equillium to Present at the Stifel Healthcare Conference

November 12, 2024

Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates

November 12, 2024

Equillium Announces Poster Presentation at the Society for Immunotherapy of Cancer

November 11, 2024

Equillium Maintains Rights to Itolizumab Following Ono Partnership

October 30, 2024

Equillium Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer

October 6, 2024

Equillium to Present at the Stifel Virtual Inflammation & Immunology Summit

September 9, 2024

Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

September 3, 2024

Equillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26th Annual Global Investor Conference

August 27, 2024

Equillium Reports Second Quarter 2024 Financial Results and Provides Recent Corporate and Clinical Highlights

August 7, 2024

Equillium Announces Positive Interim Analysis from Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease

August 5, 2024

Equillium Announces Second Quarter 2024 Estimated Cash and Investments Balance

July 17, 2024

Equillium to be included in the Russell Microcap® Index

June 11, 2024

Equillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia Areata

June 3, 2024

Equillium to Present at the Jefferies Global Healthcare Conference

May 28, 2024

Equillium Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease

May 13, 2024

Equillium Reports First Quarter 2024 Financial Results and Provides Recent Clinical Highlights

May 8, 2024

Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists

May 6, 2024

Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis

March 31, 2024

Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights

March 24, 2024

Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference and the LD Micro Invitational Conference

March 21, 2024

Decks in 2024